Abstract
Aim:
CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear.
Methods:
Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented.
Results:
A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months; median overall survival was 11 months. Treatment was well tolerated.
Conclusion:
Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.
Keywords:
HER2-; breast; cancer; heavily pretreated; hormone receptor positive; metastatic; palbociclib.
MeSH terms
-
Adult
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Female
-
Humans
-
Kaplan-Meier Estimate
-
Middle Aged
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Piperazines / administration & dosage
-
Piperazines / adverse effects
-
Piperazines / therapeutic use*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Receptor, ErbB-2 / metabolism
-
Receptors, Estrogen / metabolism
-
Receptors, Progesterone / metabolism
-
Retreatment
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyridines
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Receptor, ErbB-2
-
palbociclib